Ravulizumab for COVID-19
Official Title
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome
Study Details
This study intends to evaluate the safety and efficacy of ravulizumab for the treatment of COVID-19 severe pneumonia, acute lung injury or acute respiratory distress syndrome (ARDS).
Principal Investigator
Dr. Hrishikesh Kulkarni
IRB Number
202005120
NCT ID
Eligibility
1. Participants must be 18 or older and admitted to Barnes Jewish Hospital
2. Participants must have have either severe pneumonia, Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) associated with a confirmed COVID 19 infection (caused by a virus called Severe Acute Respiratory Syndrome-CoronaVirus 2 or SARS CoV 2)
Volunteer Information
For more information about this study, contact Volunteer for Health at:
- 314.362.1000
- rprstaff@wustl.edu